Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study to Assess the Safety and Efficacy of D-0316 in Patients With Locally Advanced/Metastatic Non Small Cell Lung Cancer Whose Tumors Are Epidermal Growth Factor Receptor Mutation Positive

NCT03861156 is registered in ClinicalTrials.gov with InventisBio Co., Ltd as lead sponsor.

NCT NCT03861156
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03861156 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study to Assess the Safety and Efficacy of D-0316 in Patients With Locally Advanced/Metastatic Non Small Cell Lung Cancer Whose Tumors Are Epidermal Growth Factor Receptor Mutation Positive
Lead sponsor
InventisBio Co., Ltd
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2019
Completion date
May 31, 2023
Enrollment
290 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr t790m, nsclc, solid tumor